Prelude Capital Management’s Fulgent Genetics FLGT Stock Holding History

Prelude Capital Management’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$895K	Buy	56,309 +18,813	+50%	+$408K	0.07%	335
2025 Q4	$985K	Sell	37,496 -31,697	-46%	-$822K	0.07%	315
2025 Q3	$1.56M	Buy	69,193 +232	+0.3%	+$4.78K	0.12%	213
2025 Q2	$1.37M	Sell	68,961 -14,850	-18%	-$289K	0.13%	189
2025 Q1	$1.42M	Buy	83,811 +68,368	+443%	+$1.16M	0.11%	215
2024 Q4	$285K	Buy	+15,443	New	+$302K	0.02%	820
2020 Q2	–	Sell	-942	Closed	-$10K	–	2048
2020 Q1	$10K	Sell	942 -6,505	-87%	-$90.6K	﹤0.01%	1130
2019 Q4	$96K	Sell	7,447 -5,185	-41%	-$61.6K	﹤0.01%	1120
2019 Q3	$131K	Buy	+12,632	New	+$120K	0.01%	865

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Prelude Capital Management's FLGT Position: Q1 2026 in Review

Prelude Capital Management increased its Fulgent Genetics (FLGT) stake by 50% in Q1 2026, buying an estimated $408K and bringing the position to 56,309 shares worth $895K. The position accounts for 0.07% of the portfolio, ranked #335.

Prelude Capital Management first reported a position in FLGT in Q3 2019 and has held it in 9 quarters since. The position peaked at $1.56M in Q3 2025. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

Prelude Capital Management held 56,309 shares of Fulgent Genetics worth $895K as of Q1 2026.
Prelude Capital Management bought 18,813 Fulgent Genetics shares in Q1 2026, an estimated $408K.
Fulgent Genetics made up 0.07% of Prelude Capital Management's portfolio in Q1 2026, its #335 holding.
Prelude Capital Management first reported a position in Fulgent Genetics in Q3 2019 and has held it in 9 quarters since.
Prelude Capital Management's Fulgent Genetics position peaked at $1.56M in Q3 2025.
157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.